Literature DB >> 26888947

Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al.

Paul Emery1, Jiří Vencovský2, Jeehoon Ghil3.   

Abstract

Keywords:  Autoantibodies; DMARDs (biologic); Rheumatoid Arthritis

Mesh：

Substances：

Year:  2016        PMID： 26888947     DOI： 10.1136/annrheumdis-2016-209203

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  2 in total

1.  52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.

Authors:  Paul Emery; Jirí Vencovský; Anna Sylwestrzak; Piotr Leszczynski; Wieslawa Porawska; Asta Baranauskaite; Vira Tseluyko; Vyacheslav M Zhdan; Barbara Stasiuk; Roma Milasiene; Aaron Alejandro Barrera Rodriguez; Soo Yeon Cheong; Jeehoon Ghil
Journal:  Rheumatology (Oxford)       Date:  2017-12-01       Impact factor: 7.580

Review 2.  Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.

Authors:  Till Uhlig; Guro L Goll
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.